Article ; Online: SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
2021 Volume 12, Page(s) 629193
Abstract: Hyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or cytokine release syndrome (CRS), is one of the key aspects of the currently ongoing SARS-CoV-2 pandemic. This process occurs when a large number of innate and adaptive ... ...
| Abstract | Hyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or cytokine release syndrome (CRS), is one of the key aspects of the currently ongoing SARS-CoV-2 pandemic. This process occurs when a large number of innate and adaptive immune cells activate and start producing pro-inflammatory cytokines, establishing an exacerbated feedback loop of inflammation. It is one of the factors contributing to the mortality observed with coronavirus 2019 (COVID-19) for a subgroup of patients. CRS is not unique to the SARS-CoV-2 infection; it was prevalent in most of the major human coronavirus and influenza A subtype outbreaks of the past two decades (H5N1, SARS-CoV, MERS-CoV, and H7N9). With a comprehensive literature search, we collected changing the cytokine levels from patients upon infection with the viral pathogens mentioned above. We analyzed published patient data to highlight the conserved and unique cytokine responses caused by these viruses. Our curation indicates that the cytokine response induced by SARS-CoV-2 is different compared to other CRS-causing respiratory viruses, as SARS-CoV-2 does not always induce specific cytokines like other coronaviruses or influenza do, such as IL-2, IL-10, IL-4, or IL-5. Comparing the collated cytokine responses caused by the analyzed viruses highlights a SARS-CoV-2-specific dysregulation of the type-I interferon (IFN) response and its downstream cytokine signatures. The map of responses gathered in this study could help specialists identify interventions that alleviate CRS in different diseases and evaluate whether they could be used in the COVID-19 cases. |
|---|---|
| MeSH term(s) | COVID-19/blood ; COVID-19/immunology ; COVID-19/pathology ; COVID-19/virology ; Cytokine Release Syndrome/blood ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Cytokines/blood ; Humans ; Inflammation/immunology ; Influenza A virus/immunology ; Influenza, Human/blood ; Influenza, Human/immunology ; Influenza, Human/virology ; Middle East Respiratory Syndrome Coronavirus/immunology ; Severe acute respiratory syndrome-related coronavirus/immunology ; SARS-CoV-2/immunology ; Severe Acute Respiratory Syndrome/blood ; Severe Acute Respiratory Syndrome/immunology ; Severe Acute Respiratory Syndrome/virology ; Severity of Illness Index |
| Chemical Substances | Cytokines |
| Language | English |
| Publishing date | 2021-03-01 |
| Publishing country | Switzerland |
| Document type | Research Support, Non-U.S. Gov't ; Systematic Review |
| ZDB-ID | 2606827-8 |
| ISSN | 1664-3224 ; 1664-3224 |
| ISSN (online) | 1664-3224 |
| ISSN | 1664-3224 |
| DOI | 10.3389/fimmu.2021.629193 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.